Cowen to host conference call to discuss third quarter financial results on Friday, October 29. Click here for more information.

Themes 2020

Targeted Therapy

Health Care Sector Icon

Why is targeted therapy a focus theme in 2020?

 

What is driving the resurgence of targeted therapies in oncology?

As tumor genomic profiling is becoming more common, investment in the capabilities to develop precision medicines against new targets and mechanisms of resistance should strengthen oncology strategy. Significant acquisitions and promising data fueled investor sentiment in 2019, and we expect continued focus on targeted therapy into 2020.

Increasingly robust understanding of the genetic mutations driving certain cancers partially de-risks the development of targeted oncology, which appeals to many investors and potential acquirers. Moreover, there will be catalysts in 2020, including potential approval and launch of a new drug in Triple Negative Breast Cancer, which alone could exceed $1 billion in sales over the next few years, in our view.

What we’re watching:

  • Capmatinib
  • KRAS
  • Sacituzumab
  • Selpercatinib
  • M&A
Themes 2020

15 Themes to Focus on 2020: A Handbook for Portfolio Managers

Download the Handbook
$100B

Expected overall sales of targeted therapies in 2023

$2.8B

Estimated TAM for kras g12c inhibitors in 2022

2x

Average overall response rate of patients treated with targeted therapies in 1L, 1L ALK+, 1L EGFR+, 1L ROS+ and 1L RET+ Settings vs. Chemo or Immuno Therapies

25%

Percentage of human cancers activated by ras mutation

Research

Podcast

Conversation with Cogent CEO Dave Schaeffer

Read More
Video

Science-Driven Wellness with Thorne CEO Paul Jacobson

Read More
Video

Scaling Gen Z Brands: A Conversation with A.K.A. Brands

Read More

Events

Virtual

Nov 29, 2021

4th Annual Cannabis Conference

Learn More
Virtual

Oct 07, 2021

10th Annual MedTools Conference – Answers Unlocked

Learn More
Virtual

Oct 05, 2021

24th Annual Therapeutics Conference

Learn More